Mumbai, Feb. 23 -- Lupin has received the approval from European Commission for its biosimilar ranibizumab, RanluspecTM (for vials and pre-filled syringes), following the recent positive opinion from the Committee for Medicinal Products for Human Use.
Published by HT Digital Content Services with permission from Capital Market....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.